loxapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychoactive 1613 1977-10-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • loxapine
  • loxapin
  • oxilapine
  • loxapine succinate
  • cloxazepine
  • loxitane
  • adasuve
  • loxapine hydrochloride
  • loxapine HCl
  • loxipine maleate
An antipsychotic agent used in SCHIZOPHRENIA.
  • Molecular weight: 327.81
  • Formula: C18H18ClN3O
  • CLOGP: 3.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 28.07
  • ALOGS: -3.50
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
9.10 mg Inhal.powder
0.10 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 355.14 34.87 139 3569 56740 50544676
Poisoning deliberate 350.56 34.87 87 3621 7825 50593591
Neuroleptic malignant syndrome 220.96 34.87 65 3643 11065 50590351
Extrapyramidal disorder 150.13 34.87 49 3659 11721 50589695
Hepatocellular injury 146.01 34.87 59 3649 25888 50575528
Cholestasis 123.36 34.87 52 3656 25349 50576067
Oculogyric crisis 111.94 34.87 25 3683 1412 50600004
Somnolence 110.60 34.87 91 3617 154894 50446522
Intestinal obstruction 92.55 34.87 43 3665 26340 50575076
Toxicity to various agents 84.23 34.87 90 3618 212409 50389007
Pneumonia aspiration 71.49 34.87 38 3670 30966 50570450
Benzodiazepine drug level increased 69.33 34.87 12 3696 175 50601241
Altered state of consciousness 65.49 34.87 32 3676 21878 50579538
Galactorrhoea 61.95 34.87 19 3689 3704 50597712
Catatonia 61.88 34.87 19 3689 3717 50597699
Intentional overdose 60.34 34.87 44 3664 62460 50538956
Hypothermia 59.61 34.87 25 3683 11991 50589425
Hyperprolactinaemia 59.52 34.87 18 3690 3347 50598069
Brain death 58.44 34.87 17 3691 2766 50598650
Faecaloma 57.21 34.87 21 3687 7087 50594329
Tachycardia 55.64 34.87 51 3657 99712 50501704
Antipsychotic drug level above therapeutic 49.77 34.87 12 3696 947 50600469
Hypotension 48.52 34.87 72 3636 235397 50366019
Hyperthermia 48.44 34.87 19 3689 7677 50593739
Miosis 48.42 34.87 18 3690 6292 50595124
Rhabdomyolysis 48.26 34.87 32 3676 38995 50562421
Intestinal pseudo-obstruction 47.30 34.87 11 3697 743 50600673
Dystonia 46.70 34.87 21 3687 11905 50589511
Cardio-respiratory arrest 45.45 34.87 35 3673 53857 50547559
Overdose 44.30 34.87 45 3663 99682 50501734
Suicide attempt 40.16 34.87 32 3676 51700 50549716
Amenorrhoea 39.90 34.87 17 3691 8467 50592949
Asphyxia 39.88 34.87 15 3693 5412 50596004
Newborn persistent pulmonary hypertension 38.21 34.87 7 3701 143 50601273
Akathisia 37.09 34.87 16 3692 8213 50593203
Anterograde amnesia 35.10 34.87 8 3700 494 50600922

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 290.06 34.31 147 5871 39303 29529206
Therapeutic product effect variable 259.36 34.31 63 5955 1814 29566695
Antipsychotic drug level below therapeutic 256.21 34.31 63 5955 1911 29566598
Disinhibition 243.61 34.31 64 5954 2543 29565966
Akathisia 239.02 34.31 78 5940 6664 29561845
Obsessive-compulsive disorder 229.39 34.31 69 5949 4507 29564002
Euphoric mood 200.48 34.31 63 5955 4762 29563747
Increased appetite 186.33 34.31 63 5955 6001 29562508
Neuroleptic malignant syndrome 160.17 34.31 74 5944 16074 29552435
Suicide attempt 130.38 34.31 83 5935 34027 29534482
Hepatocellular injury 129.61 34.31 70 5948 21173 29547336
Extrapyramidal disorder 121.16 34.31 54 5964 10777 29557732
Wrong patient received product 112.54 34.31 34 5984 2248 29566261
Rhabdomyolysis 105.48 34.31 92 5926 60716 29507793
Poisoning deliberate 102.70 34.31 40 5978 5691 29562818
Therapeutic product effect incomplete 101.25 34.31 75 5943 39230 29529279
Miosis 99.50 34.31 43 5975 7966 29560543
Dyslipidaemia 86.79 34.31 36 5982 6025 29562484
Obesity 81.82 34.31 40 5978 9823 29558686
Leukopenia 77.07 34.31 74 5944 55129 29513380
Leukaemia 76.88 34.31 29 5989 3781 29564728
Prescribed overdose 74.38 34.31 36 5982 8647 29559862
Product use in unapproved indication 72.96 34.31 89 5929 86786 29481723
Hypothermia 69.31 34.31 35 5983 9204 29559305
Somnolence 68.96 34.31 90 5928 93865 29474644
Toxicity to various agents 65.14 34.31 122 5896 173539 29394970
Weight increased 63.46 34.31 78 5940 76589 29491920
Colitis ischaemic 61.80 34.31 28 5990 5795 29562714
Hyperleukocytosis 58.22 34.31 19 5999 1616 29566893
Faecaloma 53.61 34.31 23 5995 4179 29564330
Subileus 51.42 34.31 20 5998 2830 29565679
Pneumonia aspiration 50.75 34.31 49 5969 36688 29531821
Fatigue 46.98 34.31 5 6013 316816 29251693
Bradypnoea 44.06 34.31 17 6001 2354 29566155
Blood creatine phosphokinase increased 43.06 34.31 47 5971 40597 29527912
Necrotising colitis 41.16 34.31 13 6005 995 29567514
Congestive cardiomyopathy 40.80 34.31 22 5996 6608 29561901
Tachycardia 37.75 34.31 59 5959 72351 29496158
Mydriasis 36.91 34.31 20 5998 6065 29562444
Electrocardiogram QT prolonged 36.90 34.31 41 5977 36096 29532413
Schizoaffective disorder 36.10 34.31 12 6006 1080 29567429
Hyperthermia 36.08 34.31 23 5995 9407 29559102
Compensatory sweating 35.35 34.31 6 6012 24 29568485

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 640.37 32.90 286 8449 87329 64402668
Poisoning deliberate 423.24 32.90 129 8606 13329 64476668
Neuroleptic malignant syndrome 366.97 32.90 135 8600 24861 64465136
Extrapyramidal disorder 277.31 32.90 103 8632 19449 64470548
Hepatocellular injury 268.03 32.90 128 8607 45107 64444890
Somnolence 186.58 32.90 180 8555 203465 64286532
Rhabdomyolysis 172.13 32.90 123 8612 91603 64398394
Miosis 156.02 32.90 61 8674 13205 64476792
Pneumonia aspiration 131.11 32.90 88 8647 59183 64430814
Hypothermia 129.19 32.90 60 8675 19796 64470201
Intestinal obstruction 113.18 32.90 67 8668 36219 64453778
Faecaloma 111.80 32.90 44 8691 9684 64480313
Akathisia 107.99 32.90 45 8690 11465 64478532
Wrong patient received product 105.21 32.90 33 8702 3729 64486268
Cholestasis 90.60 32.90 63 8672 44809 64445188
Catatonia 89.43 32.90 35 8700 7585 64482412
Tachycardia 88.44 32.90 105 8630 149474 64340523
Hyperthermia 85.90 32.90 42 8693 15508 64474489
Subileus 84.59 32.90 30 8705 4947 64485050
Toxicity to various agents 82.13 32.90 163 8572 363350 64126647
Altered state of consciousness 78.35 32.90 54 8681 37848 64452149
Oculogyric crisis 78.28 32.90 24 8711 2514 64487483
Blood creatine phosphokinase increased 71.54 32.90 61 8674 58497 64431500
Necrotising colitis 71.20 32.90 18 8717 926 64489071
Fatigue 71.10 32.90 9 8726 748721 63741276
Asphyxia 68.77 32.90 31 8704 9535 64480462
Cardio-respiratory arrest 68.13 32.90 75 8660 98318 64391679
Bladder dilatation 67.83 32.90 20 8715 1834 64488163
Suicide attempt 67.09 32.90 64 8671 70943 64419054
Hyperleukocytosis 65.94 32.90 20 8715 2020 64487977
Benzodiazepine drug level increased 59.86 32.90 12 8723 211 64489786
Bradypnoea 58.09 32.90 23 8712 5136 64484861
Antipsychotic drug level below therapeutic 55.98 32.90 15 8720 970 64489027
Galactorrhoea 53.18 32.90 19 8716 3200 64486797
Distal intestinal obstruction syndrome 52.27 32.90 13 8722 625 64489372
Faecal vomiting 50.74 32.90 14 8721 1011 64488986
Colitis ischaemic 50.44 32.90 28 8707 13386 64476611
Respiratory acidosis 49.62 32.90 25 8710 9830 64480167
Electrocardiogram QT prolonged 48.92 32.90 57 8678 79391 64410606
Therapeutic product effect variable 48.39 32.90 15 8720 1629 64488368
Disinhibition 47.74 32.90 16 8719 2227 64487770
Pain 47.13 32.90 9 8726 553502 63936495
Confusional state 47.12 32.90 107 8628 261037 64228960
Housebound 45.86 32.90 11 8724 454 64489543
Agitation 45.63 32.90 58 8677 88309 64401688
Congestive cardiomyopathy 45.61 32.90 24 8711 10320 64479677
Brain death 45.57 32.90 19 8716 4842 64485155
Dystonia 44.05 32.90 29 8706 18836 64471161
Product use in unapproved indication 41.91 32.90 81 8654 176537 64313460
Intentional overdose 41.72 32.90 56 8679 89888 64400109
Dyspnoea 40.04 32.90 24 8711 718650 63771347
Antipsychotic drug level above therapeutic 38.52 32.90 13 8722 1848 64488149
Hyperprolactinaemia 38.48 32.90 16 8719 4049 64485948
Psychotic disorder 38.14 32.90 34 8701 34544 64455453
Intestinal ischaemia 37.75 32.90 22 8713 11527 64478470
Urinary retention 36.63 32.90 39 8696 49162 64440835
Diabetic hyperosmolar coma 36.46 32.90 10 8725 706 64489291
Camptocormia 35.43 32.90 9 8726 472 64489525
Compensatory sweating 34.61 32.90 6 8729 45 64489952
Choking 34.25 32.90 20 8715 10518 64479479
Euphoric mood 34.00 32.90 17 8718 6574 64483423
Arthralgia 33.99 32.90 9 8726 442251 64047746
Intestinal pseudo-obstruction 33.77 32.90 12 8723 1988 64488009
Psychotic symptom 32.99 32.90 12 8723 2126 64487871

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AH01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Diazepines, oxazepines, thiazepines and oxepines
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35476 neuroleptics
CHEBI has role CHEBI:48561 dopaminergic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bipolar disorder indication 13746004 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Alcoholism contraindication 7200002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Glaucoma contraindication 23986001 DOID:1686
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Coma contraindication 371632003
Carcinoma of female breast contraindication 447782002
Pigmentary Retinopathy contraindication
Drug Induced CNS Depression contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.59 Basic
pKa2 3.24 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 7.68 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.62 CHEMBL CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.82 PDSP
Sodium-dependent noradrenaline transporter Transporter Ki 5.24 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 5.61 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8 IUPHAR
5-hydroxytryptamine receptor 6 GPCR Ki 7.82 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.51 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.97 PDSP
D(3) dopamine receptor GPCR ANTAGONIST IC50 7.66 CHEMBL
D(1B) dopamine receptor GPCR Ki 7.13 PDSP
Histamine H1 receptor GPCR ANTAGONIST Ki 8.20 IUPHAR
Histamine H2 receptor GPCR Ki 6.68 PDSP
Histamine H4 receptor GPCR Ki 5.30 PDSP
Muscarinic acetylcholine receptor M1 GPCR IC50 5.26 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 6.38 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 6.91 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 6.09 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 6.83 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.41 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.10 PDSP
D(4) dopamine receptor GPCR ANTAGONIST Ki 8.31 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel Ki 6.72 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.28 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.11 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.85 PDSP
Potassium channel subfamily K member 2 Ion channel IC50 4.70 CHEMBL
Potassium channel subfamily T member 1 Ion channel ACTIVATOR EC50 5.36 IUPHAR
5-hydroxytryptamine receptor 1D GPCR Ki 5.46 PDSP
D(1A) dopamine receptor GPCR Ki 7.27 PDSP
D(2) dopamine receptor GPCR Ki 7.68 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 8.22 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.37 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 6 CHEMBL
Histamine H1 receptor GPCR IC50 6 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.80 IUPHAR
Adrenergic receptor alpha-1 GPCR IC50 7.74 CHEMBL

External reference:

IDSource
4019805 VUID
N0000147894 NUI
D00794 KEGG_DRUG
27833-64-3 SECONDARY_CAS_RN
54810-23-0 SECONDARY_CAS_RN
4017917 VANDF
4017918 VANDF
4019805 VANDF
C0024056 UMLSCUI
CHEBI:50841 CHEBI
CHEMBL831 ChEMBL_ID
CHEMBL1201155 ChEMBL_ID
DB00408 DRUGBANK_ID
D008152 MESH_DESCRIPTOR_UI
3964 PUBCHEM_CID
205 IUPHAR_LIGAND_ID
2610 INN_ID
LER583670J UNII
1364415 RXNORM
1308 MMSL
1346 MMSL
196711 MMSL
29026 MMSL
4999 MMSL
5000 MMSL
d00897 MMSL
001522 NDDF
001523 NDDF
001524 NDDF
1971003 SNOMEDCT_US
30745005 SNOMEDCT_US
372789006 SNOMEDCT_US
59270007 SNOMEDCT_US
CHEMBL1201060 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1394 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1395 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1396 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1397 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0369 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0370 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0371 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0372 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-585 TABLET 5 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-586 TABLET 10 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-587 TABLET 25 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-588 TABLET 50 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 17856-1397 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-436 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-437 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-438 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-439 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4701 CAPSULE 10 mg ORAL ANDA 21 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4701 CAPSULE 10 mg ORAL ANDA 21 sections
Adasuve HUMAN PRESCRIPTION DRUG LABEL 1 51097-001 AEROSOL, POWDER 10 mg RESPIRATORY (INHALATION) NDA 31 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-890 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-891 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-892 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-893 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 68151-2875 CAPSULE 5 mg ORAL ANDA 18 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0283 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0283 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0346 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0346 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0347 CAPSULE 25 mg ORAL ANDA 20 sections